Cardlytics, Inc. (CDLX)

Current Report Filed: 2026-05-07

Cardlytics released Q1 2026 earnings results on May 7, 2026, indicating the company is maintaining regular financial reporting cadence and investor communication practices.
The 8-K filing is a routine earnings announcement with no indication of material events, acquisitions, leadership changes, or significant corporate developments beyond standard quarterly results disclosure.
The filing was signed by David Evans, CFO, confirming proper financial officer authorization and that results were officially announced via press release (Exhibit 99.1) rather than as filed financial statements.

Quarterly Report Filed: 2026-05-07

Cardlytics filed Q1 2026 10-Q on May 7, 2026, covering the period ending March 31, 2026, indicating timely regulatory compliance with SEC filing requirements.
The filing shows multiple debt instruments including 2024 Convertible Senior Notes and revolving credit facilities, suggesting the company is managing a capital structure that includes both convertible debt and traditional credit lines.
Presence of discontinued operations related to Bridg (noted in XBRL taxonomy) indicates prior divestitures or business unit separations that may impact year-over-year comparisons and operating performance analysis.
The company maintains equity compensation programs including restricted stock units (RSUs) and performance shares with multiple vesting tranches, reflecting standard executive incentive structures for talent retention.
Multiple references to international operations (GB country designation) suggest Cardlytics operates or has exposure outside the United States, introducing foreign exchange and regulatory complexity.

Insider Trading Filed: 2026-04-06

Insider Amit Gupta, the Chief Executive Officer, sold 69,833 shares of Cardlytics, Inc. (CDLX) stock on April 6, 2026 to satisfy tax withholding obligations from the vesting of RSUs.
The shares were sold at a weighted average price of $1.187, which is within the reported range of $1.135 to $1.230 per share.
Gupta continues to beneficially own 987,387 shares of Cardlytics stock following the reported sale.

Current Report Filed: 2026-03-24

Cardlytics, Inc. has completed the sale of its Bridg platform to PAR Technology Corporation for consideration of 1,810,222 shares of PAR's common stock.
The unaudited pro forma condensed consolidated financial statements provide insights into the financial impact of the Bridg platform divestiture on Cardlytics' financials.
The transaction allows Cardlytics to focus on its core business and could potentially improve its financial performance going forward.

Current Report Filed: 2026-03-04

Cardlytics, Inc. reported its Q4 2025 and full-year 2025 financial results, highlighting the company's recent corporate developments.
The company provided information regarding an upcoming conference call to discuss the financial results and recent highlights.
Investors will be interested in analyzing the company's revenue trends, margin changes, and any guidance or risk factors presented in the upcoming earnings call.

Annual Report Filed: 2026-03-04

Cardlytics, Inc. (CDLX) reported a net loss of $22.3 million in fiscal year 2025, a significant improvement from the $32.5 million net loss in the previous year, indicating progress in the company's profitability.
The company's revenue grew by 12% year-over-year in fiscal year 2025, reaching $380.2 million, driven by growth in the Cardlytics Platform US segment, which accounts for the majority of the company's business.
Cardlytics' acquisition of HSPEPI Acquisition LLC in December 2023 for $55.2 million appears to have been a strategic move to expand the company's capabilities and market reach.

Insider Trading Filed: 2026-03-03

Amit Gupta, the CEO of Cardlytics, Inc. (CDLX), has been granted a substantial award of 1,500,000 restricted stock units (RSUs), indicating the company's commitment to retaining its key executive.
The RSUs will vest over a two-year period, aligning Gupta's interests with those of Cardlytics' shareholders and providing an incentive for him to continue driving the company's success.
The large size of the RSU award, representing a significant portion of Gupta's overall equity stake, suggests the board's confidence in his leadership and the company's future growth prospects.

Insider Trading Filed: 2026-02-20

The reporting person, Nicholas Lynton Hollmeyer, was granted 220,000 restricted stock units (RSUs) as the Chief Legal & Privacy Officer of Cardlytics, Inc.
The RSUs will vest in equal amounts quarterly over a two-year period through April 1, 2028, provided that the reporting person remains employed by the company.
This RSU grant represents a long-term incentive and alignment of the reporting person's interests with those of the company and its shareholders.

Current Report Filed: 2026-01-26

Cardlytics, Inc. (CDLX) has entered into an asset purchase agreement to sell its Bridg platform to PAR Technology Corporation (PAR) for up to $30 million in PAR common stock.
The sale of the Bridg platform is a strategic move for Cardlytics, allowing it to focus on its core business and optimize its operations.
The transaction is subject to customary closing conditions and is expected to be completed by March 24, 2026.

Insider Trading Filed: 2026-01-16

David Thomas Evans, the Chief Financial Officer of Cardlytics, Inc., received 1,000,000 restricted stock units (RSUs) on January 12, 2026, which will vest over a two-year period.
The RSU grant represents a significant equity award for the CFO, signaling the company's commitment to retaining key leadership.
The vesting schedule, with 50% vesting in the first year and the remaining 50% vesting over the next year, suggests a focus on long-term alignment between the CFO and shareholders.

Important Information